Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | AGPAT2 | O15120 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29634149 | 0.81 | PTGDR2 (0.57) | ERN1AGPAT2ALDH1A1KDM4EHPGD | |
| SCHEMBL3759371 | 0.81 | PTGDR2 (0.57) | ERN1AGPAT2ALDH1A1KDM4EHPGD | |
| SCHEMBL7699644 | 0.80 | ALDH1A1 (0.56) | ERN1AGPAT2ALDH1A1KDM4EHPGD | |
| SCHEMBL10093048 | 0.80 | AGPAT2 (0.57) | ERN1AGPAT2ALDH1A1KDM4EHPGD | |
| SCHEMBL2753744 | 0.80 | CA12 (0.50) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL2785782 | 0.79 | ALDH1A1 (0.53) | ERN1AGPAT2ALDH1A1KDM4EHPGD | |
| SCHEMBL5988696 | 0.79 | HPGD (0.65) | ERN1AGPAT2ALDH1A1KDM4EHPGD | |
| SCHEMBL11513966 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL5326539 | 0.79 | ERN1 (0.52) | ERN1MEN1KMT2ASMN1; SMN2USP2 | |
| SCHEMBL9254425 | 0.77 | ERN1 (0.49) | ERN1AGPAT2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | claimed |
| EP-3116851-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | Salk Institute for Biological Studies (US) | 2017-01-18 | — | — | EP | claimed |
| WO-2015138969-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | claimed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-05-20 | — | — | US | disclosed |
| US-10815203-B2 | Analogs of fexaramine and methods of making and using | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200123113-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-04-23 | — | — | US | disclosed |
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-10-22 | — | — | US | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9173887-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015138969-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | ERN1 3110/4885AGPAT2 4315/4885ALDH1A1 3511/4885 |
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | ERN1 3163/4885AGPAT2 1834/4885ALDH1A1 1412/4885 |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | ERN1 160/4885AGPAT2 1656/4885ALDH1A1 1137/4885 |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | ERN1 160/4885AGPAT2 1656/4885ALDH1A1 1137/4885 |
| US-10815203-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | ERN1 3163/4885AGPAT2 1834/4885ALDH1A1 1412/4885 |
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | ERN1 3163/4885AGPAT2 1834/4885ALDH1A1 1412/4885 |
| US-20200123113-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | ERN1 3163/4885AGPAT2 1834/4885ALDH1A1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.